Inclusion Criteria:  Willing and able to sign written informed consent prior to study entry. Participants who self-identify as Asian; male or female, >18 years of age. Established diagnosis of type 2 diabetes (documented by either HbA1c 6.5 - 10.0% or a documented diagnosis of type 2 diabetes). Treatment naïve or on active therapy with metformin at a daily dose of 500-3000 mg at screening. Dose of metformin must have been stable for at least 3 months prior to screening. Participants must have a hematocrit value greater than or equal to 34.0% for females and 40% for males. Participants must have a hemoglobin value greater than or equal to 11.0 g/dL for females and 13.5 g/dL for males.  Exclusion Criteria:  Fasting plasma glucose >220 mg/dl at screening. Impaired kidney function, eGFR of <60 mL/min/1.73 m2 at screening. BMI >35 kg/m2. Weight ≤ 50 kg. Elevated liver transaminase > 3 ULN at screening. Ongoing or recent (i.e. < 3 month) treatment with any oral or injectable glucose-lowering drug other than metformin. Ongoing or recent (i.e. < 3 month) injectable insulin therapy. Ongoing or recent (i.e. < 3 month) weight loss interventions (e.g. dietary weight loss programs) or any history of bariatric surgery or any documented weight loss >5% within previous 6 months. Ongoing or recent (i.e. < 3 month) treatment with anorectic drugs, systemic steroids, medications known to affect gastric motility, or any condition known to affect gastro-intestinal integrity and food absorption. Major medical/surgical event requiring hospitalization in the last 3 months. Known allergy and intolerance to product components or paracetamol. Alcohol intake higher than 2 servings per day. A serving is 0.4 dl of strong alcohols, 1 dl of red or white wine, or 3 dl of beer. Are unable to comply with protocol procedures in the opinion of the investigator. Have a hierarchical link with the research team members. Positive pregnancy test or breast-feeding at screening. Participants who have been dosed in another clinical study with any investigational drug/new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to screening. Donation of blood or significant amount of blood loss within 8 weeks prior to screening. Participants must also agree to not donate blood within 8 weeks after their last visit.